-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
-
- Properties
-
Overview
- Home
- Products
- Life Science
- Analytical Chromatography
- Antibodies
- Assay Kits
- Antigens
- Biochemical Reagents
- Biospecimens
- Cell Culture
- Cell Analysis
- Chemicals
- Cloning and Expression
- Collagen
- Nucleic Acid Detection
- Nucleic Acid Extraction
- Enzymes
- Glycan Analysis
- Hydrogels
- Immunohistochemistry (IHC)
- Ion Exchange Resins
- Liposomes
- Microbiology
- Nanoparticles
- Nucleic Acid Electrophoresis
- Nucleic Acid Synthesis
- PCR
- Proteins
- Protein Biochemistry
- Protein Gel Electrophoresis
- Transfection Reagents
- Ubiquitin-Proteasome
- Venoms
- Lab Solutions
- Amerigo Scientific Instrument
- 3D Bioprinting
- Medical Devices
- Life Science
- Services
- About Us
- Contact Us
.
